For millions of people at high risk of heart disease, keeping cholesterol under control remains a lifelong struggle. Now, a major medical breakthrough has raised hopes: a single infusion that permanently edits a liver gene and sharply lowers “bad” cholesterol for at least a year.
That is the possibility opened up by early results from VERVE-102, an experimental gene-editing medicine being tested by global pharmaceutical giant Eli Lilly. If confirmed in larger studies, it could shift cardiovascular care from lifelong management to one-time treatment.
